Living With T1D/August 9, 2026/2 min read

What's Changing in Type 1 Diabetes Access and Treatment This Month

From a new insulin biosimilar to shifts in insurance coverage, recent developments are reshaping how people with Type 1 diabetes get care. Here's what you need to know.

Video report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

living with t1dtechnologysupport

Key takeaways

The FDA approved Garzoulies, a biosimilar version of NovoLog (insulin aspart), marking the third aspart biosimilar available in the US
Hawaii passed a law requiring insurers to cover continuous glucose monitors, expanding access for residents
A new projection suggests nearly 500,000 Medicaid beneficiaries with diabetes could lose coverage by 2034 without policy changes
Biosimilars are highly similar to original insulins but are not new types of insulin—whether they affect what patients pay depends on pricing and insurance decisions not yet announced

A Third Aspart Biosimilar Enters the Market

The FDA has approved Garzoulies, a biosimilar of NovoLog (insulin aspart), a rapid-acting insulin used at mealtime. This marks the third aspart biosimilar to receive FDA clearance in the United States.

It's important to understand what a biosimilar is: it's a medication that is highly similar to an already-approved biologic drug, but it is not a new kind of insulin. Garzoulies works the same way as the original NovoLog.

At this stage, the manufacturer has not announced a US price or launch date. That means it's unclear whether this approval will change what patients pay out of pocket or how insurers cover the drug. These details typically emerge closer to when a medication becomes available.

Hawaii Expands Continuous Glucose Monitor Coverage

Hawaii has enacted SB3045, a law that requires insurers operating in the state—including Medicaid managed care plans—to cover continuous glucose monitors (CGMs). This expansion makes CGMs more accessible for Hawaii residents with diabetes who previously may not have had coverage.

Continuous glucose monitors are tools that help people with Type 1 diabetes track blood sugar in real time, and access to them varies widely by state and insurance plan.

Major Medicaid Coverage Concern Emerging

The American Diabetes Association has released a projection warning that nearly 500,000 Medicaid beneficiaries with diabetes could lose coverage by 2034 if current policies don't change.

This is a projection based on expected policy trends, not a definite outcome. The warning underscores the importance of policy advocacy to protect insurance access for people with diabetes who rely on Medicaid.

Evidence label

Origin: YouTube / T1D Pulse (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.